Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity

Annals of the New York Academy of Sciences

Volumn 965, Issue , 2002, Pages 254-266

  Battaglia, G ^a   Gesi, M ^b   Lenzi, P ^b   Busceti, C L ^a   Soldani, P ^b   Orzi, F ^a,c   Rampello, L ^d   Nicoletti, F ^a,c   Ruggieri, S ^a   Fornai, F ^b  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Apomorphine; Dopaminergic neurons; Methamphetamine; MPTP; Neuroprotection; Neurorescue

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; HYPOTHERMIA; IMMUNOHISTOCHEMISTRY; MALE; MINIPUMP; MORPHOLOGY; MOUSE; NERVE ENDING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE;

ANIMALIA;

EID: 0036296950     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04167.x     Document Type: Conference Paper

References (51)

1. Methamphetamine and methilenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction
2. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations
3. Long-term methamphetamine-induced changes in brain catecholamine in tolerant rhesus monkeys
4. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
5. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration
6. Long-term effects of repeated metylamphetamine administration on dopamine and serotonin neurons in the rat brain: Regional study
7. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain
8. Role for excitatory amino acids in methamphetamine-induced nigro-striatal dopaminergic toxicity
9. Treatment of mice with methamphetamine produces cell loss in the substantia nigra
10. Inhibition of monoamine oxidase by d-methamphetamine
11. 3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine
12. Amphetamine redistributes dopamine from synaptic vescicles to the cytosol and promotes reverse transport
13. Multiple methamphetamine injections induced marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity
14. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular stress
15. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: Impact of methamphetamine
16. Dopamine transporters and neuronal injury
17. The effects of methamphetamine on the production of free radicals and oxidative stress
18. Oxydative pathway for catecholamines in the genesis of neuromelanin and cytotoxic quinones
19. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system
20. Neurochemical and neurogenetic correlates of Parkinson's disease
21. The site of dopamine formation in rat striatum after L-DOPA administration
22. Dopamine agonists in Parkinson's disease: A look at apomorphine
23. Does levodopa aggravate Parkinson's disease?
24. Pathophysiology of L-DOPA induced dyskinesia
25. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction
26. Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines
27. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators
28. Apomorphine protects against MPTP-induced neurotoxicity in mice
29. Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance
30. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa-induced interdose dyskinesias in Parkinson's disease
31. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part I: Systemic administration
32. + kinetics and MPTP-induced nigrostriatal dopamine depletions
33. The ontogeny of aggregation-enhanced toxicity
34. The role of locus coeruleus in the development of Parkinson's disease
35. Protein measurement with the Folin phenol reagent
36. Effects of pretreatment with DSP-4 on methamphetamine-induced striatal dopamine loss and pharmacokinetics
37. Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxylase activity in mice
38. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol
39. 2 receptor agonists with high and low efficacies
40. Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4- methylaminobenzamide (YM-09151-2) with selective anti-dopaminergic activity
41. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage
42. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction
43. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons
44. A synergistic neurotrophic response to 1-dihydroxyphenylalanine and nerve growth factor
45. Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxilase activity
46. Role of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine system
47. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
48. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases
49. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years
50. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease